Dogwood Therapeutics, Inc. (DWTX)

Market Cap	60.17M +546.4%
Revenue (ttm)	n/a
Net Income	-36.04M
EPS	-1.71
Shares Out	33.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,673
Open	1.800
Previous Close	1.700
Day's Range	1.700 - 1.800
52-Week Range	1.280 - 9.500
Beta	1.83
Analysts	Buy
Price Target	14.00 (+690.96%)
Earnings Date	Nov 5, 2026

About DWTX

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: DWTX
• Website: https://dwtx.com

Analyst Summary

According to 2 analysts, the average rating for DWTX stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 690.96% from the latest price.

Price Target

$14.0

(690.96% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 17, 2026

Data Sources Report a data error